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Abstract
Background: Histamine is an amine widely known as a peripheral inflammatory mediator and as a neurotransmitter in
the central nervous system. Recently, it has been suggested that histamine acts as an innate modulator of microglial
activity. Herein, we aimed to disclose the role of histamine in microglial phagocytic activity and reactive oxygen species
(ROS) production and to explore the consequences of histamine-induced neuroinflammation in dopaminergic (DA)
neuronal survival.
Methods: The effect of histamine on phagocytosis was assessed both in vitro by using a murine N9 microglial cell line
and primary microglial cell cultures and in vivo. Cells were exposed to IgG-opsonized latex beads or phosphatidylserine
(PS) liposomes to evaluate Fcγ or PS receptor-mediated microglial phagocytosis, respectively. ROS production and
protein levels of NADPH oxidases and Rac1 were assessed as a measure of oxidative stress. DA neuronal survival was
evaluated in vivo by counting the number of tyrosine hydroxylase-positive neurons in the substantia nigra (SN) of
mice.
Results: We found that histamine triggers microglial phagocytosis via histamine receptor 1 (H1R) activation and ROS
production via H1R and H4R activation. By using apocynin, a broad NADPH oxidase (Nox) inhibitor, and Nox1 knockout
mice, we found that the Nox1 signaling pathway is involved in both phagocytosis and ROS production induced by
histamine in vitro. Interestingly, both apocynin and annexin V (used as inhibitor of PS-induced phagocytosis) fully
abolished the DA neurotoxicity induced by the injection of histamine in the SN of adult mice in vivo. Blockade of H1R
protected against histamine-induced Nox1 expression and death of DA neurons in vivo.
Conclusions: Overall, our results highlight the relevance of histamine in the modulation of microglial activity that
ultimately may interfere with neuronal survival in the context of Parkinson’s disease (PD) and, eventually, other
neurodegenerative diseases which are accompanied by microglia-induced neuroinflammation. Importantly, our
results also open promising new perspectives for the therapeutic use of H1R antagonists to treat or ameliorate
neurodegenerative processes.
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Background
Histamine is a biogenic amine with extensive effects on
several peripheral immune cells and recently highlighted
as a promising modulator of brain innate immunity. In
the brain, it is produced by histaminergic neurons, mast,
and microglial cells [1–6]. Histamine exerts its various
functions through the activation of four distinct subtypes
of G protein-coupled receptors (H1R, H2R, H3R, and
H4R) [7, 8]. Microglial cells, the innate immune cells in
the central nervous system, express all histamine recep-
tors [9], and we were the first to show that histamine
modulates N9 microglial cells migration and interleukin-
1β (IL-1β) release [7]. Other studies also showed that
histamine may also modulate the release of IL-1β, tumor
necrosis factor (TNF)-alpha, IL-6, nitric oxide (NO), re-
active oxygen species (ROS) production and induce
mitochondrial membrane potential dysfunction [8–13].
Interestingly, the functional consequences of histamine
in microglial phagocytosis remain unexplored. Microglia
phagocytose foreign pathogens, stressed/apoptotic cells,
and also supernumerary synapses in postnatal develop-
ment. Several microglia receptors enable the recognition
of these targets, namely Fc-gamma receptors (FcγR),
which bind to IgG of opsonized particles, and phosphati-
dylserine (PS) receptors (PSR), which bind to PS on the
outer membrane leaflet of stressed and apoptotic cells.
Several other receptors can recognize the exposed PS,
such as T cell/transmembrane, immunoglobulin, and
mucin (TIM) -1, TIM-4, and the vitronectin receptor
[14–16]. Overall, phagocytosis is considered to be bene-
ficial since it eliminates stressed/apoptotic cells and
maintains healthy neuronal networks. However, phago-
cytosis can also activate the respiratory burst cascade,
which produces toxic ROS ultimately inducing cytotox-
icity [16, 17]. In particular, the nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase (Nox) system is
responsible for producing ROS that are associated with
microglial phagocytosis and neuronal death [18, 19]. Ac-
cordingly, herein, we found that histamine induces
microglial phagocytosis via H1R activation and ROS pro-
duction via both H1R and H4R activation. Both micro-
glial responses depend on the activation of the Nox
system. Therefore, histamine may have an impact on the
pathogenesis of brain diseases which are associated with
inflammatory conditions. In fact, increased levels of his-
tamine found in the cerebrospinal fluid (CSF) and in
brain parenchyma as well as pharmacological experi-
ments and clinical trials suggest that the histaminergic
system may be implicated in the etiology and/or pro-
gression of several neurodegenerative diseases [20, 21]
such as Parkinson’s disease (PD) [22–25]. In fact, it has
been shown that the substantia nigra (SN) is a brain re-
gion highly vulnerable to the neurotoxic actions of
microglia [14, 26] and in particular to histamine [27].
Recently, we also showed that the secretome of micro-
glial cells exposed to histamine induces degeneration of
dopaminergic (DA) neurons in vitro [8]. However, the
cellular and molecular mechanisms behind these toxic
effects are not known. Importantly, our present results
also highlight the potential of H1R antagonists to pre-
vent DA cell loss derived from histamine-induced micro-
glial neuroinflammation in vivo. Altogether, we present
novel findings that unravel the effects of histamine in
microglial-induced DA neuronal death and the potential
therapeutic application of H1R antagonist to counteract
these toxic effects.
Methods
N9 microglial cell line cultures
Murine N9 microglia cell line was grown in modified
Roswell Park Memorial Institute (RPMI) medium (Sigma-
Aldrich, St. Louis, MO, USA) during 24 h at 37 °C in 5 %
CO2 and 95 % atmospheric air, as previously described by
us [28]. Cells were plated at a density of 2 × 104 cells per
well in 24-well trays (phagocytic studies and immunocyto-
chemistry), 5 × 105 cells per well in 6-well trays (protein
extraction), or 5 × 104 cells per well in 96-well trays (ROS
measurements). Cell treatments included the following in-
cubation setup: histamine dihydrochloride (1, 10, and
100 μM, Sigma-Aldrich), H1R antagonist (mepyramine
maleate, 1 μM), H2R antagonist (cimetidine, 5 μM), H3R
antagonist (carcinine ditrifluoroacetate, 5 μM), H4R
antagonist (JNJ7777120, 5 μM), H1R agonist (2-pyridy-
lethylamine dihydrochloride, 100 μM), H4R agonist (4-
methylhistamine dihydrochloride, 20 μM) (all from Tocris
Bioscience, Bristol, UK), and apocynin (5 μM, Sigma-
Aldrich). All histamine receptor antagonists and apocynin
were added 1 h prior to cell treatments and maintained
during the course of the experiments.
Primary murine microglia cell cultures
Postnatal whole brain microglia cultures of wild-type
(WT) and Nox1 knockout (Nox1-KO) mice were pre-
pared as previously reported [29]. Briefly, the whole
brain of 3–5-day postnatal mice pups were dissected,
carefully stripped of meninges, and mechanically dissoci-
ated with a 5-ml pipette, followed by 5–10 sequential
passages through 20-, 22-, and 25-gauge needles. Finally,
cells were passed through a 70 μm mesh, pelleted by
centrifugation, suspended in high-glucose Dulbecco’s
modified Eagle medium (DMEM) with 10 % fetal bovine
serum (FBS) and 100 units/ml penicillin plus 100 μg/ml
streptomycin (all from Sigma-Aldrich), and plated onto
25 cm2 poly-D-lysine-coated culture flasks (one brain
per flask). The cultures were kept at 37 °C in a 5 % CO2,
95 % air atmosphere. The medium was changed every
4 days. On day 14, the culture flasks were shaken during
2 h at 200 rpm to detach microglial cells, leaving
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astrocytes in an adherent monolayer. The microglia-
enriched supernatant was collected and centrifuged for
10 min at 1200 rpm. The pellet was then suspended in
DMEM, and the microglial cells were plated onto poly-
D-lysine-coated coverslips and kept at 37 °C in a 5 %
CO2, 95 % air atmosphere until used. The culture
medium was replaced every 4 days. Each pup was geno-
typed to confirm its phenotype as WT or Nox1-KO.
In vitro phagocytosis assays
FcγR-mediated phagocytosis
Latex beads (Sigma-Aldrich) were opsonized with rabbit
IgG (1 μg/ml, Sigma-Aldrich) under constant agitation
overnight at 4 °C. Then, the beads were resuspended
in modified RPMI medium without NaHCO3 (Sigma-
Aldrich) and distributed at a density of 1 × 105 beads per
well, over cells that were previously exposed to histamine
for 6 h. After 40 min of incubation with the beads, the
cells were washed with phosphate-buffered saline (PBS)
and fixed with 4 % paraformaldehyde (PFA, Sigma-
Aldrich) for 20 min at room temperature (RT). Extracellu-
lar and/or adherent beads were labeled with secondary
antibody Alexa Fluor 594 donkey anti-rabbit (1:500, Life
Technologies Ltd, Paisley, UK) in PBS, for 1 h at RT. For
nuclear labeling, cell preparations were stained with
Hoechst 33342 (2 μg/ml, Life Technologies Ltd.) in PBS,
for 5 min at RT. Coverslips were then mounted in Dako
fluorescent medium (Dakocytomation Inc., Glostrup,
Denmark). Confocal images were acquired using an
Axio Observer LSM710 confocal microscope (Zeiss)
under a 63× oil objective. For each coverslip, five photo-
micrographs were acquired in order to capture stained nu-
clei (in blue), extracellular and/or adherent beads (in red),
and the total number of beads (differential interference
contrast image). The location of each bead was analyzed
by comparing the three separate images simultaneously.
Only beads without fluorescent labeling were considered
as internalized particles.
PS-mediated phagocytosis
Fluorescent-labeled PS or phosphatidylcholine (PC)-con-
taining liposomes (5 μl/well) were added to the cells pre-
viously exposed to histamine for 6 h. PC liposomes were
used as a negative control for PS-dependent phagocyt-
osis. To block PS-induced phagocytosis, annexin V
(4 μl/well), which binds to PS residues, was added 1 h
prior to incubation with liposomes. After 2 h of expos-
ure to liposomes, the cells were washed with RPMI
medium and then fixed with 4 % PFA. After several
rinses with PBS, unspecific binding was prevented by in-
cubating cells in a 3 % BSA and 0.5 % Triton X-100 so-
lution (all from Sigma-Aldrich) in PBS, for 30 min at
RT. Then, the cells were incubated overnight at 4 °C
with primary antibody rat monoclonal anti-CD11b
(1:600; AbD Serotec, Oxford, UK) diluted in PBS con-
taining 0.3 % BSA and 0.1 % Triton X-100. After several
washes with PBS, the cells were incubated for 1 h at RT
with the corresponding secondary antibody Alexa Fluor
488 goat anti-rat (1:200; Life Technologies Ltd) diluted
in PBS. For nuclear labeling, cell preparations were
stained with Hoechst 33342 (2 μg/ml; Life Technologies
Ltd) in PBS, for 5 min at RT and mounted in a Dako
fluorescent medium. Fluorescent images were acquired
using an Axio Observer LSM710 confocal microscope
(Zeiss) under a 40× oil objective. Photomicrographs were
acquired using the same acquisition settings in each ex-
perimental protocol. For each experimental setting, we
first outlined microglial cytoplasm by staining CD11b (in
green) and the corrected fluorescence intensity of PS/PC
liposomes (in red) was subtracted from the fluorescence
background. Similar protocols reported by others were
used to quantify microglial phagocytosis of synaptic inputs
(presynaptic terminals), axonal or myelin debris, and
neurofilament-positive axonal material [30–32]. Quantifi-
cation of fluorescence intensity of the PS/PC liposomes
was performed with at least 64 cells per condition. Ana-
lysis was performed using the ImageJ software.
Liposome preparation
Liposomes (diameter 2–6 μm) were prepared by a classical
Bangham technique. Multilamellar vesicles were chosen
to maximize the fluorescent-dye load per particle without
significant self-quenching [33]. Briefly, dioleoyl phosphat-
idylcholine (Avanti Polar Lipids, Alabama, USA) and chol-
esterol (Sigma-Aldrich) were mixed in chloroform at 1:1
molar ratio, and DiIC18(3) dye (Life Technologies Ltd.)
was added; this dye has two stearyl residues attached to
the fluorochrome, so it is tightly attached to the liposome
membrane and is not exchangeable. PS (Avanti Polar
Lipids) was added at 1:10 PS to PC mass ratio to the ex-
perimental sample but not to control. After chloroform
removal by rotary evaporation and argon gas flush, vac-
uum desiccation was applied to remove traces of organic
solvent. After the complete removal of the solvent, normal
saline was added to the lipid film and the sample was sub-
jected to hydration under vortexing.
Measurements of cellular ROS levels
ROS levels were measured using a dihydroethidium
probe (DHE, Life Technologies Ltd), as described previ-
ously by us [34]. In the DHE assay, blue fluorescent
DHE is dehydrogenated by superoxide (O2
−) to form red
fluorescent ethidium bromide. The cells exposed for 2 h
to stimuli were then incubated for 4 h (N9 cell line)
or 20 min (primary murine microglial cells) with
100 μM DHE in culture medium at 37 °C. The emitted
fluorescence (excitation 515 nm; emission 605 nm) was
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read in a spectrofluorometer (SpetroMax GeminiEM;
Molecular Devices).
Immunocytochemistry
The cells were fixed with 4 % PFA, and unspecific binding
was prevented by incubating cells in a 3 % BSA and 0.5 %
Triton X-100 solution (all from Sigma-Aldrich) for 30 min
at RT. The cells were incubated with primary antibodies
prepared in 0.3 % BSA and 0.1 % Triton X-100, kept
overnight at 4 °C, washed with PBS, and finally incu-
bated for 1 h at RT with the corresponding secondary
antibody. Antibodies used were as follows: rat monoclonal
anti-CD11b (1:600; AbD Serotec), mouse monoclonal
anti-acetylated α-tubulin (1:100; Sigma-Aldrich), goat
polyclonal anti-Nox1 (1:250; Santa Cruz Biotechnology,
Heidelberg, Germany), Alexa Fluor 594 goat anti-rat,
Alexa Fluor 488 goat anti-rat, Alexa Fluor 488 donkey
anti-goat, and Alexa Fluor 594 rabbit anti-mouse (all
1:200 in PBS, from Life Technologies Ltd). Membrane ruf-
fling was observed using phalloidin, a marker for filament-
ous actin. The cells were incubated for 2 h with Alexa
Fluor 594 conjugated to phalloidin (1:100; Life Technolo-
gies Ltd) in PBS, at RT. For nuclear labeling, cell prepara-
tions were stained with Hoechst 33342 (2 μg/ml, Life
Technologies Ltd) in PBS, for 5 min at RT and mounted
in Dako fluorescent medium. Fluorescent images were
acquired using an Axio Observer LSM710 confocal micro-
scope (Zeiss) under a 63× oil objective.
Western blotting
The cells were washed with ice-cold PBS and lysed on
ice in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 2 mM sodium orthovanadate, 1 % Nonidet-P40,
0.5 % sodium deoxycholate, 0.1 % SDS, and 1 % of a pro-
tease inhibitor mixture containing 4-(2-aminoethyl)ben-
zenesulfonyl fluoride hydrochloride, pepstatin A, E-64,
bestatin, leupeptin, and aprotinin, all from Sigma-
Aldrich). After gentle homogenization, the total amount
of protein was quantified using the Bradford method
(Bio-Rad Protein Assay, Bio-Rad, Hertz, UK). After-
wards, the samples were loaded onto 12 % acrylamide/
bisacrilamide gels (Bio-Rad). Proteins were separated by
SDS-PAGE and then transferred to PVDF membranes
(Amersham HybondTM-P, GE Healthcare, Little Chal-
font, UK). The membranes were then blocked with 5 %
non-fat milk in Tris-buffered saline with 0.1 % Tween
20 (TBS-T) for 1 h at RT. Incubation with mouse mono-
clonal anti-acetylated α-tubulin (1:200; Sigma-Aldrich),
goat polyclonal anti-Nox1 (1:200; Santa Cruz Biotech-
nology), goat polyclonal anti-Nox2 (1:2000; BD Labora-
tories, San Jose, CA, USA), goat polyclonal anti-Nox4
(1:200; Santa Cruz Biotechnology), and mouse monoclo-
nal anti-Rac1 (1:750; Millipore, Billerica, MA, USA) di-
luted in TBS-T was done overnight at 4 °C. After rinsing
three times with TBS-T, the membranes were incubated
for 1 h at RT with an anti-mouse (1:10,000; GE Health-
care) or anti-goat antibody (1:10,000; Santa Cruz Bio-
technology) diluted in TBS-T. The membranes were
then incubated with ECF substrate (ECF Western Blot-
ting Reagent Packs, GE Healthcare) for 5 min. Protein
bands were detected using the Molecular Imager FX sys-
tem (Bio-Rad) and quantified by densitometry analysis
using the Quantity One software (Bio-Rad).
In vivo experiments
Wild-type C57BL/6 male mice (8 to 12 weeks) were main-
tained in appropriate cages, under temperature-controlled
environment under a 12 h light/dark cycle with free access
to food and water. All experiments related to the use of
experimental animal models were conducted in compli-
ance with protocols approved by the national ethical re-
quirements for animal research, the European Convention
for the Protection of Vertebrate Animals Used for Experi-
mental and Other Scientific Purposes (European Union
Directive number 2010/63/EU). Before stereotaxic sur-
gery, the mice were anesthetized with an intraperitoneal
injection (i.p.) of ketamine and xylazine (90 mg/kg and
10 mg/kg, respectively).
To analyze DA neuronal survival, the mice were uni-
laterally injected with 2 μl of sterile PBS or histamine
(100 μM in PBS) in the right lateral SN (coordinates re-
lated to the bregma: AP = +3.0 mm; ML = −1.4 mm; DV
= −4.4 mm; according to [35]) using a stereotaxic frame
(Stoelting 51600, IL, USA). In another set of animals,
2 μl of sterile H1R antagonist (mepyramine maleate,
1 μM) or H4R antagonist (JNJ7777120, 5 μM) were also
injected following histamine administration. Stereotaxic
injections were made using a 10 μl Hamilton syringe
(Hamilton Company) at a rate of 0.2 μl/min during
10 min. The needle was removed and the incision su-
tured. Apocynin (4 mg/kg, i.p.) or annexin V (5 μg/
mouse, intravenously (i.v.)) were administrated 30 min
before and also 24 h after stereotaxic injections, as de-
scribed previously by others [33, 36]. Seven-day (for DA
neuronal survival analysis) or 3-day (for co-localization
between CD11b+/TH+/annexin V, Nox1+/CD11b+ or
Nox1+/TH+) upon all injections, the mice were trans-
cardially perfused with 0.9 % NaCl and fixed with 4 %
PFA. The brains were removed and post-fixed in 4 %
PFA overnight at 4 °C. After fixation, the brains were
cryoprotected in 30 % sucrose (in 0.1 M PBS) at 4 °C
until sinking, frozen in liquid nitrogen, and maintained
at −80 °C. Before sectioning, the brains were embedded
in an optimal cutting temperature medium (OCT) and
cut into 35-μm coronal sections using a cryostat-
microtome (Leica CM3050S, Leica Microsystems) at
−20 °C. Slices corresponding to the SN of each animal
Rocha et al. Journal of Neuroinflammation  (2016) 13:137 Page 4 of 16
were collected for immunohistochemical processing, as
described previously by us [37].
For the in vivo phagocytosis assays, the mice were
stereotaxically injected into the right SN with 1 μl of PS
liposomes followed by histamine treatment (as described
above). Perfusion was performed 18 h after the stereo-
taxic injections. The brains were removed, fixed in 4 %
PFA, and cut as stated previously. Floating sections
(35 μm) were then analyzed for phagocytic cells (CD11b
+ cells with liposome detection).
Fluorescent immunohistochemistry staining
SN slices were permeabilized with 1 % Triton X-100 in
0.1 M PBS, for 45 min at RT. Non-specific binding sites
were blocked with 10 % FBS in PBS for 30 min at RT. In
a group of slices, permeabilization was performed only
after incubation with Alexa Fluor 488 annexin V conju-
gate. Then, the slices were incubated with the primary
antibodies: rat monoclonal anti-CD11b (1:600; AbD
Serotec), goat polyclonal anti-Nox1 (1:200; Santa Cruz
Biotechnology), and mouse monoclonal anti-TH anti-
body (1:1000; BD Laboratories), diluted in 10 % FBS in
PBS, overnight at 4 °C. After several washes with 0.1 %
Triton X-100 (PBS-T), the slices were incubated with
the respective secondary antibodies, Alexa Fluor 594 or
488 goat anti-rat, Alexa Fluor 647 anti-mouse, or Alexa
Fluor 546 anti-goat (all 1:200; Life Technologies Ltd) di-
luted in PBS, for 2 h at RT. Following nuclei counter-
staining with Hoechst 33342 (2 μg/ml; Life Technologies
Ltd) in PBS for 5 min at RT, the sections were mounted
in glass slides with a Dako mounting medium. Fluores-
cent images were acquired using an Axio Observer
LSM710 confocal microscope (Zeiss) under a 63× oil ob-
jective. To quantify microglial phagocytosis of liposomes,
three distinct brain slices containing the SN [37] were se-
lected per mouse, and in each slice, three pictures were
taken within a range of approximately 200 μm from the li-
posomes injection site. The volume of CD11b-positive
cells containing PS liposomes was then quantified by
orthogonal analysis as described previously [33].
Immunohistochemistry for Tyrosine Hydroxylase (TH)
Free-floating immunohistochemistry was initiated by in-
cubating SN sections in a 10 mM citrate solution (pH
6.0) at 80 °C [37]. After cooled to RT, the slices were
placed in water for 5 min and then washed in PBS-T.
The sections were blocked with 10 % FBS in PBS for 1 h
at RT and washed twice with PBS-T. For the inhibition
of endogenous peroxidase activity, the brain sections
were incubated for 10 min in 3 % H2O2. This step was
followed by two washes with PBS-T. Incubation with
mouse monoclonal anti-TH antibody (1:1000; BD La-
boratories) diluted in 5 % FBS in PBS was performed
overnight at 4 °C. After washing with PBS-T, the
slices were incubated for 1 h at RT with a biotinyl-
ated goat anti-mouse antibody (1:200; Vector Laborator-
ies, Peterborough, UK) diluted in 1 % FBS. The sections
were washed again and incubated with the avidin–biotin
peroxidase complex reagent (ABC kit from Vector Labora-
tories) for 30 min at RT. Then, the sections were
developed using 3,3′-diaminobenzidine (Sigma-Aldrich) in
TBS with 30 % H2O2, mounted onto Superfrost precleaned
coated slides, dehydrated through a graded ethanol series,
cleared using xylene and coversliped with Entellan mount-
ing medium (Merck, Kenilworth, NJ, USA). Quantitative
analysis of DA neurons in SN was carried out by serial sec-
tion analysis of the total number of TH-positive neurons
throughout the rostro-caudal axis. The region correspond-
ing to the SN was carefully delineated and the total num-
ber of TH-positive neurons in the full extent of this
structure was counted per section in each hemisphere, as
described previously by us [37].
Data analysis
Data are expressed as percentage of values obtained in
control conditions or as percentage of the total number
of cells and are presented as mean ± SEM of at least
three independent experiments. Statistical analysis was
performed using paired or unpaired t test (whenever ap-
propriate) or one-way ANOVA followed by Bonferroni’s
multiple comparison test, as indicated in the figure leg-
ends. Values of P < 0.05 were considered significant. All
statistical procedures were performed using GraphPad
Prism 5 (GraphPad Software Inc.).
Results
Histamine promotes microglial phagocytosis
We first evaluated the effect of histamine on FcγR-
mediated phagocytosis in murine N9 microglial cell line.
Microglial cells were allowed to internalize IgG-opson-
ized latex beads for 40 min followed by an incubation
with a secondary antibody Alexa Fluor 594 to distinguish
extracellular and/or adherent beads (red labeling) from
internalized beads (no fluorescent labeling) (Fig. 1a).
Phagocytosis was addressed by counting the total num-
ber of internalized beads per cell. We showed that IgG
bead phagocytosis increased with escalating concentra-
tions of histamine, reaching about a 2.5-fold increase
when 100 μM histamine was added to cells (P < 0.001,
Fig. 1a, b). At this concentration, histamine did not
interfere with cell death or proliferation (data not
shown). Based on these results and on prior studies re-
ported by us [8, 38, 39], we then used 100 μM histamine
in further experiments, a concentration of pathophysio-
logical relevance. In order to identify which histamine
receptor was involved in phagocytosis, we treated micro-
glial cells with the antagonists for each receptor before
histamine treatment. Our results showed that only H1R
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antagonist (mepyramine maleate, 1 μM) significantly
abolished histamine-induced phagocytosis when com-
pared with histamine per se (P < 0.001, Fig. 1b). Consist-
ently, an H1R agonist (2-pyridylethylamine, 100 μM)
was able to mimic the effect induced by histamine
(Fig. 1b). Antagonists for H2R (cimetidine, 5 μM), H3R
(carcinine ditrifluoroacetate, 5 μM) or H4R (JNJ7777120,
5 μM) were not efficient in abolishing histamine-induced
phagocytosis (Fig. 1b). These data suggest that histamine-
induced FcγR-microglial phagocytosis of opsonized beads
via H1R activation.
Then, we determined whether histamine could also
modulate PSR-mediated phagocytosis using fluorescent
PS or PC liposomes, as described in [33]. For this pur-
pose, N9 microglial cells were exposed to 100 μM hista-
mine for 6 h followed by 2 h incubation with PS or PC
liposomes (Fig. 2a). We found that histamine signifi-
cantly increased by twofold the phagocytosis/uptake of
PS liposomes (P < 0.05; Fig. 2a). Annexin V which binds
to PS residues was used as an inhibitor of PS-induced
phagocytosis. As expected, annexin V fully abolished the
histamine-induced uptake of PS liposomes (Fig. 2a). No
significant differences were found in the levels of PC
liposomes phagocytosis when cells were treated with his-
tamine as compared to the controls (histamine: 139.7 ±
29.2 as compared with the control — set to 100 %, n =
3–4). Then, we evaluated the effect of histamine in
microglia phagocytosis in vivo by injecting histamine in
the SN of mice followed by PS liposomes. The volume
of CD11b-positive (+) cells (resident microglial cells/in-
vading macrophages) containing PS liposomes was
quantified as described previously by others [33]. As ex-
pected, histamine significantly increased the percentage
of volume of CD11b+ cells containing PS liposomes as
compared with saline mice (P < 0.05; Fig. 2b). The
physiological relevance of the aforementioned results
was then validated by investigating the ability of micro-
glial cells to phagocyte PS residues on the membrane of
stressed/dying neurons upon histamine exposure in vivo.
The stereotaxic injection of histamine in the SN for
Fig. 1 Histamine-induced microglial FcγR-mediated phagocytosis through H1R activation. a Representative photomicrographs illustrate the stimulatory
effect of 100 μM histamine on microglial phagocytosis of IgG latex beads. Non-ingested beads display red labeling whereas ingested beads do
not show any fluorescence signal. Scale bar 10 μm. b Only 10 (H10) and 100 (H100) μM histamine significantly increased the number of phagocytosed
IgG latex beads per cell as compared with untreated controls (Ctr). Microglial phagocytosis induced by 100 μM histamine was fully blocked by an H1R
antagonist (AntH1R, mepyramine maleate, 1 μM) and mimicked by an H1R agonist (AgH1R, 4-methylhistamine dihydrochloride, 20 μM).
The involvement of other receptors was excluded since the application of their respective antagonists (“Ant”) did not interfere with the
phagocytosis-inducing effect of histamine (H2R antagonist (cimetidine), 5 μM; H3R antagonist (carcinine ditrifluoroacetate), 5 μM; and H4R
antagonist (JNJ7777120), 5 μM). Data are expressed as mean ± SEM (n = 5–15). *P < 0.05 and ***P < 0.001, using one-way ANOVA followed
by Bonferroni’s multiple comparison test
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3 days triggered a relative higher number of co-
localization events between CD11b+, TH+, and annexin
V+. These co-localization events were less evident in sa-
line animals (Fig. 2c). Altogether, these results suggest
that histamine induces phagocytosis of particles and cells
displaying PS residues on their surfaces both in vivo and
in vitro, likely increasing the vulnerability of stress/dying
neurons to microglia phagocytosis.
Histamine triggers microglial cytoskeleton modifications
To further explore the cytoskeleton modifications be-
hind histamine-mediated phagocytosis, microglial cells
were stimulated with 100 μM histamine for 1 h for
actin filaments (phalloidin staining), and for 12 or
24 h for microtubule stabilization evaluation (acety-
lated α-tubulin protein levels). Histamine-induced
membrane ruffling by actin polymerization and
Fig. 2 Histamine-induced microglial phagocytosis of PS particles/residues. a Bar graph displays the stimulatory effect of 100 μM histamine (H100) on
the phagocytosis of phosphatidylserine (PS)-conjugated liposomes in vitro. Specific effect on PS-induced phagocytosis was ruled out by using annexin
V (AnxV). Data are expressed as mean ± SEM (n = 2–10) and as a percentage of control. *P < 0.05, using one-way ANOVA followed by Bonferroni’s
multiple comparison test. Right panel: representative photomicrographs illustrate the stimulatory effect of 100 μM histamine on microglial phagocytosis
of PS liposomes in vitro. PS liposomes: red labeling; CD11b: green labeling; nuclei (Hoechst 33342): blue. Scale bar 10 μm. b The bar graph
represents the volume of CD11b+ cells containing PS liposomes in SN slices from mice injected intracranially with 100 μM histamine for 18 h.
Data are expressed as mean ± SEM (n = 4–6 mice) and as a percentage of saline. *P < 0.05, using an unpaired t test as compared with saline mice.
Right panel: representative photomicrographs illustrate the stimulatory effect of histamine on microglial phagocytosis of PS liposomes in vivo.
PS liposomes: red labeling; CD11b: green labeling; nuclei (Hoechst 33342): blue. Arrows highlight co-labeling events. Scale bar 10 μm.
c Representative confocal photomicrographs showing that the stereotaxic injection with 100 μM histamine (H100) in the SN of adult mice for
3 days induced co-localization (highlighted with white arrows) between PS residues (green), CD11b labeling (red), and TH dopaminergic neuronal staining
(white). This co-localization was less evident in saline animals. Cell nuclei were stained with Hoechst 33342 (in blue). Scale bar 10 μm
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punctuate staining in structures involved in the initi-
ation of phagocytosis (Fig. 3a). In addition, we found
that in unstimulated microglial cells (control) acety-
lated α-tubulin staining was found predominantly con-
fined to the centrosome tubules (Fig. 3b). In contrast,
histamine induced an increase of acetylated α-tubulin
labeling particularly in several microglial processes
that may be involved in the stabilization of phagocytic
cups/protrusions (Fig. 3b). In accordance, acetylated
α-tubulin protein expression levels were significantly
increased by histamine (1.8-fold increase, P < 0.001) at
24 h post-treatment as compared with the controls
(Fig. 3c). These results suggest that histamine induces
cytoskeleton alterations associated with microglia
phagocytosis dynamics.
Oxidative stress contribution to histamine-induced micro-
glial phagocytosis
Then, we evaluated the effect of histamine on ROS pro-
duction and the putative contribution of ROS for micro-
glial phagocytosis. As shown in Fig. 4a (N9 cell line) and
in Additional file 1: Figure S1 (primary murine microglia
cells), 100 μM histamine significantly increased ROS
levels when compared to control (P < 0.001). ROS
Fig. 3 Histamine-induced microglial cytoskeleton rearrangement. a Representative confocal photomicrographs showing that 100 μM histamine (H100)
induced membrane ruffling. Cells were stained for phalloidin (red), CD11b (green), and Hoechst 33342 (nuclei in blue). b Histamine also
increased α-tubulin acetylation expression levels especially in some microglial processes (white arrows) as compared with the faint staining
present in microtubule organization centers (asterisk) found in resting microglial cells, as detected by immunolabeling for acetylated α-tubulin
(red), CD11b (green), and Hoechst 33342 (nuclei in blue). Scale bars 10 μm. c Bar graph displays the increased expression levels of acetylated α-tubulin
in histamine-activated cells. Data are expressed as mean ± SEM (n = 4–8) and as a percentage of control. ***P < 0.001, using one-way ANOVA followed
by Bonferroni’s multiple comparison test
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production induced by 100 μM histamine was fully
inhibited by H1R or H4R antagonists (Fig. 4b and Add-
itional file 1: Figure S1) and mimicked by H1R (P < 0.01)
or H4R (P < 0.05) agonists (Fig. 4b). The co-
administration of both H1R and H4R antagonists with
histamine blocked histamine-induced ROS production
to the same level as both antagonists individually
(data not shown). These data suggest that histamine-
induced ROS production occurs via H1R and H4R ac-
tivation, both in N9 cell line and primary murine
microglia cell cultures. Then, apocynin was used to
clarify the specific role of the Nox system in micro-
glia ROS generation induced by histamine. Apocynin
significantly inhibited histamine-induced ROS produc-
tion in N9 microglial cells to levels similar to the con-
trols (P < 0.001, Fig. 4c). Interestingly, apocynin also fully
abrogated histamine-induced IgG beads phagocytosis (P <
0.05, Fig. 4d). The concentration of apocynin used did not
interfere with microglial cell death as evaluated by ter-
minal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) and propidium iodide (PI) assays (data
not shown). These results suggest that Nox activation and
subsequent ROS production are involved in histamine-
induced phagocytosis. Accordingly, histamine significantly
increased Nox1 protein levels at 6 and 12 h post-
treatment, both in the N9 cell line and primary murine
microglial cells (Fig. 5a, b). Nox1 labeling was found pref-
erentially at the luminal side of the plasma membrane,
suggesting membrane recruitment of Nox1 signaling cas-
cade (Fig. 5c). In contrast, no differences were observed
regarding Nox2 and Nox4 expression levels in histamine-
treated cells as compared with the controls (Additional file
2: Figure S2). Functional activation of Nox1 is dependent
on the activation of a small GTPase, Rac1. We found that
histamine increased the expression levels of Rac1 1 h after
treatment, both in the N9 cell line and primary murine
microglial cells (Fig. 5d, e). To prove the involvement of
Nox1 signaling pathway on histamine-induced phagocyt-
osis, we performed the same IgG bead phagocytosis proto-
col on primary cultures of microglial cells obtained from
Fig. 4 Histamine-induced ROS generation contributes to microglial phagocytosis. a Only 10 (H10) and 100 μM histamine (H100) significantly increased
the levels of ROS as compared with untreated controls (Ctr). b Cellular ROS production induced by 100 μM histamine was blocked by an
H1R antagonist (AntH1R, mepyramine maleate, 1 μM) or H4R antagonist (AntH4R, JNJ7777120, 5 μM) and mimicked by an H1R agonist
(AgH1R, 4-methylhistamine dihydrochloride, 20 μM) or a H4R agonist (4-methylhistamine dihydrochloride, 20 μM). The involvement of other receptors
was excluded since the application of their respective antagonists did not interfere with ROS levels induced by histamine (H2R antagonist (cimetidine),
5 μM; H3R antagonist (carcinine ditrifluoroacetate), 5 μM). Apocynin (5 μM) was used to rule out the involvement of the NADPH oxidase
system in cellular production of ROS (c) and in the phagocytosis of IgG latex beads (d) induced by histamine. Apocynin-treated cells are
represented in slashed columns both in (c and d). Data are expressed as mean ± SEM (n = 3–16) and as a percentage of control. *P < 0.05,
**P < 0.01, and ***P < 0.001, using one-way ANOVA followed by Bonferroni’s multiple comparison test
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Nox1-KO mice and matched WT littermates. We found
that Nox1 deficiency inhibits histamine-induced phagocyt-
osis (Fig. 5f). Altogether, these results suggest that the
Nox1/Rac1 signaling and the resultant ROS production are
involved in histamine-induced microglial phagocytosis.
Histamine-induced microglial activation modulates DA
neuronal survival via H1R activation
We then explored the consequences of histamine-
induced microglia activation in DA neuronal survival in
vivo. We found that the stereotaxic injection of hista-
mine in the SN of adult C57BL/6 mice for 7 days in-
duced about 40–50 % decrease of TH+ cells as
compared with saline-treated mice (P < 0.001; Fig. 6a, b).
To disclose the involvement of histamine receptors, we
then co-injected histamine with the H1R or H4R antago-
nists in the SN. We found that only H1R antagonist was
able to abolish the neurotoxic effect of histamine
(Fig. 6a). Histamine-induced DA toxicity was also abol-
ished by annexin V and apocynin (AnX V +H100: 108.9
± 3.0; Apo +H100: 84.9 ± 10.9; n = 5, as compared with
saline mice — set to 100 %; Fig. 6a). Annexin V or apoc-
ynin per se did not modify significantly the number of
TH+ cells as compared with saline animals (data not
shown). In accordance with previous in vitro data (Fig. 5),
Nox1 protein levels were increased in the SN of
histamine-treated mice (Fig. 6c, d). H1R antagonist com-
pletely abolished histamine-induced Nox1 expression
(Fig. 6c). Nox1 labeling was found predominantly in the
perinuclear region of microglial cells (Fig. 6e).
Altogether, our findings suggest that histamine, via H1R
activation, induces microglial activation and ultimately
the death of susceptible DA neurons, possibly by Nox1-
dependent oxidative signaling and PS-mediated micro-
glial phagocytosis.
Discussion
Herein, we aimed to disclose the role of histamine and
its receptors in microglia activation, namely in phagocyt-
osis and ROS production, and ultimately to explore the
Fig. 5 Rac-1/Nox1 signaling is involved in microglial phagocytosis triggered by histamine. a Bar graph depicting Nox1 protein expression levels
upon treatment with 100 μM histamine (H100) for 6 or 12 h, both in the N9 cell line and primary microglial cell cultures. Data are expressed as
mean ± SEM (n = 4–10) and as a percentage of control. *P < 0.05 and **P < 0.01, using Bonferroni’s multiple comparison test as compared with
control. b Representative Nox1 (65 kDa) and GAPDH (37 kDa) Western blots in primary microglial cell cultures. c Representative confocal photomicrographs
showing that 100 μM histamine-induced Nox1 expression in the luminal side of the plasma membrane of N9 microglial cells (highlighted by white arrows).
Cells were stained for CD11b (red), Nox1 (green), and Hoechst 33342 (nuclei in blue). Scale bar 10 μm. d Bar graph depicting Rac1 protein expression levels
upon treatment with 100 μM histamine (H100) for 1 h, both in the N9 cell line and primary microglial cell cultures. Data are expressed as mean ± SEM
(n = 3–8) and as a percentage of control. *P < 0.05 using paired t test as compared with control. e Representative Rac1 (22 kDa) and GAPDH
(37 kDa) Western blots in primary microglial cell cultures. f Bar graph displays the effect of histamine on the phagocytosis of IgG latex beads in Nox1
knockout mice (KO) and their respective wild-type (WT) littermates. Data are expressed as mean ± SEM (n = 4) and as a percentage of control.
***P < 0.001 using Bonferroni’s multiple comparison test as compared with control
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functional consequences of this inflammatory response
in DA neuronal survival.
First, we found that histamine induces the phagocyt-
osis of IgG-opsonized latex beads via H1R activation.
This is in accordance with other reports showing that
histamine can also induce phagocytosis in macrophages
[40, 41]. In contrast, other reports argue that histamine
inhibits macrophage phagocytosis [42, 43]. These contra-
dictory studies may be due to the different types of cells
used, range of histamine concentrations, and/or different
experimental protocols. On the other hand, microglial
cells have other surface receptors that recognize PS resi-
dues exposed on the surface of cells that underwent
apoptosis or were subjected to certain stressing agents.
The PS exposure acts as “eat-me” signals that can be
recognized by microglial cells as targets to be eliminated
[44, 45]. We found that histamine could also potentiate
phagocytosis/uptake of PS liposomes. Annexin V was
able to inhibit histamine-induced PS phagocytosis, dem-
onstrating that this process depends on the exposure of
PS residues by liposomes. Interestingly, histamine in-
duces both types of FcγR- and PSR-induced microglia
phagocytosis, apparently triggering opposite inflamma-
tory responses to the engulfment of distinct cargo.
Classically, FcγR phagocytosis is associated to a M1
pro-inflammatory microglial phenotype, whereas M2
anti-inflammatory phenotype is mainly associated to
PSR-phagocytosis. However, classic activation paradigms
driving an M1 phenotype also lead to enhanced engulf-
ment of apoptotic cells in vitro [46]. On the other hand,
M2 phenotype driven by IL-4 and IL-13 increases the
phagocytosis of myelin [47], whereas a M2 phenotype in-
duced by glioma cancer stem cells reduces phagocytosis
[48]. This suggests that histamine may be a versatile im-
mune modulator by activating a particular phagocytosis
pathway depending on a particular context.
Fig. 6 Histamine induces DA toxicity via H1R activation and involves oxidative stress and PS-mediated phagocytosis. a Bar graph depicts the percentage
of TH+ cells in the SN of mice. A significant reduction in the number of TH+ neurons was found in 100 μM histamine (H100)-treated mice as compared
with saline. Antagonist (Ant) for H1R abolished the toxicity induced by histamine. The toxic effect induced by histamine involves the production of ROS
and PS-induced phagocytosis, since both apocynin (“Apo”, NADPH oxidase inhibitor) and annexin V (“AnxV”, blocker of PS residues) could inhibit
dopaminergic toxicity. Data are expressed as mean ± SEM (n = 4–7 mice) and as a percentage of saline animals. *P < 0.05 and ***P < 0.001,
using one-way ANOVA followed by Bonferroni’s multiple comparison test. b Representative immunostainings for TH in the SN of adult mice. A
notable decrease in the number of TH+ cells could be observed in mice injected with histamine when compared with saline animals. c Bar graph
depicts Nox1 protein expression levels in the SN. Increased expression of Nox1 protein found in histamine (H100)-treated mice was completely abolished
by the H1R antagonist. Data are expressed as mean ± SEM (n= 4 mice). *P< 0.05 and **P < 0.01, using one-way ANOVA followed by Bonferroni’s multiple
comparison test. d Representative Nox1 (65 kDa) and GAPDH (37 kDa) Western blots in the SN of adult mice in vivo. e Representative confocal
photomicrographs showing that histamine-induced Nox1 expression in the perinuclear region of microglial cells in the SN in vivo. Cells were stained
for CD11b (green), Nox1 (red), and Hoechst 33342 (nuclei in blue). White arrows highlight Nox1 staining in microglial cells. Scale bar 10 μm
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Activated microglia also release an inflammatory cock-
tail, including cytokines, phagocytic adaptor proteins
(e.g., Milk Fat Globule-EGF Factor 8 Protein - MFG-E8),
ROS, and NO, that may interfere with neuronal survival.
Previously, we showed that histamine induces NO re-
lease by microglial cells [8]. Neither IL-1β nor tumor ne-
crosis factor (TNF)-α was released upon histamine
stimulation in the N9 microglial cell line that we used
[7]. Herein, we show that histamine induces ROS pro-
duction via H1R and H4R activation. A recent study
showed that histamine induces TNF-α, IL-6 and ROS
production and loss of mitochondrial membrane poten-
tial in rat primary microglial cultures, primarily via H1R
and H4R activation [10]. Both H1R and H4R activate
phospholipase C (PLC) [49, 50]. PLC can activate either
PLC-inositol triphosphate (IP3) leading to intracellular
calcium increase or PLC-protein kinase C (PKC) which
in turn initiates nuclear factor (NF)-kappaB activation
and can induce increased gene transcription, including
inducible nitric oxide synthase (iNOS) expression and
NO release [51–53]. This redundant and superimposed
signaling pathways induced by H1R and H4R may medi-
ate the release/production of inflammatory mediators
(including NO and ROS) differently involved in several
steps of microglial activity. Herein, our results demon-
strated that histamine may also induce Rac1/Nox1 sig-
naling triggering increased ROS levels which are
responsible for microglia phagocytosis. Previous reports
described that in microglia [54] and in DA neurons [55],
Nox1 transcriptional regulation is modulated by
PKCdelta. As mentioned above, this is especially import-
ant taking into account that H1R may activate PLC
which is known to be the upstream regulator of
PKCdelta activity. Moreover, it was recently reported
that in dorsal root ganglion neurons, histamine activates
PKCdelta via H1R [53]. Based on these assumptions, we
may speculate that the downstream histamine signaling
pathway may involve the activation of PLC by H1R,
followed by PKCdelta activation inducing increased
Nox1 expression and activation culminating in increased
ROS production. In a number of studies, the involve-
ment of Nox2 in microglia-dependent DA neurotoxicity
has been also observed [56, 57]. These findings raise the
question on whether other Nox isoforms are involved in
microglia inducing oxidative stress in the nigrostriatal
DA pathway. In the present work, we observed that
Nox1 has a critical role in microglia phagocytosis as
shown by experiments using Nox1-KO microglia cul-
tures. Nevertheless, it is also plausible that microglia
Nox2 may have a participation, probably in an upstream
step, that with time is abolished given place to Nox1-
inducing oxidative stress by microglia. In the present
work, we are also showing that histamine increases PS-
mediated microglia phagocytosis. Oxidation of PS is
crucial for its externalization, and it was previously re-
ported that Nox-dependent ROS generation is respon-
sible for the selective oxidation of PS in neutrophils [58].
In addition, Brown and Neher [44] have shown that per-
oxynitrite produced by microglia is responsible for the
externalization of PS on target cells to potentiate its
phagocytosis. Also in this line, a study has shown that
in activated microglia the O2− produced by Nox1 may
increase the levels of peroxynitrite that may diffuse and
affect neighboring target cells [19]. Altogether, this sup-
ports the outcome of our results showing that in micro-
glia, histamine increase Nox1 expression which is
responsible for increasing ROS production and PS oxi-
dation in target cells potentiating its phagocytosis.
The downstream signaling pathways induced by both
FcγR and PSR receptor activation lead to the remodeling of
the microglial cytoskeleton through actin polymerization
which is involved in the formation of pseudopodia. The for-
mation of pseudopods is coincident with local remodeling
of the cortical actin cytoskeleton and the formation of
phagocytic cups involved in target engulfment [16, 59]. In
fact, we observed that histamine induced a robust actin
punctuate staining in membrane ruffles. In accordance, we
previously showed that LPS promotes microglial phagocyt-
osis by modulating actin cytoskeleton reshuffling and the
formation of phagocytic cups [60]. We also observed that
histamine induced an increase of acetylated α-tubulin
levels, localized preferentially along microglial processes.
Acetylation of α-tubulin is a post-translational modification
that serves as a marker of microtubule stabilization which
is essential for spreading and phagocytosis [61]. These cyto-
skeleton modification events involving both actin
polymerization and tubulin stabilization require activation
of Rho GTPases, namely Rac1 and cdc42 [62–64]. This is
in agreement with the increased levels of Rac1 expression
induced by histamine in our microglial cell line. Rac1 is in-
volved in the activation of Nox, in particular the Nox1 iso-
form, but also in cytoskeleton alterations required for
microglial phagocytosis.
We then hypothesize that histamine-induced microglial
activation could be related to the modulation of DA sur-
vival in vivo. In accordance with previous studies [27, 65],
histamine was able to induce DA neuronal death accom-
panied by microglial reactivity. The neurotoxic effect in-
duced by histamine was prevented by blocking H1R.
Recently, it was also shown that histamine impairs mid-
brain DA development in vivo via H1R activation [66].
However, so far, the cellular and molecular mechanisms be-
hind histamine-induced DA toxicity in the adult brain in
vivo are not known. We hypothesize that histamine may in-
duce an inflammatory milieu that encompasses increased
ROS levels that triggers DA neurons to expose PS on their
outer membrane leaflet stimulating microglial phagocytosis,
oxidative stress, and ultimately DA neuronal death. Indeed,
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we found that histamine induces DA neuronal death via
H1R activation, an effect accompanied with increased
Nox1 protein levels. Interestingly, in the present experi-
mental in vivo paradigm, Nox1 was found in the peri-
nuclear region of the microglial cells. Additionally, Nox1
expression was also found in neurons (Additional file 3:
Figure S3), as we have previously showed that Nox1 is up-
regulated on neurons in response to other in vivo injury
paradigms such as ischemia or paraquat and 6-
hydroxydopamine (6-OHDA)-mediated neuronal death
[34, 67, 68]. Therefore, we cannot exclude the putative in-
volvement of neuronal Nox1 activation in the modulation
of DA cell survival in vivo. We also found that histamine-
induced PS exposure in the membranes of DA neurons and
annexin V was able to abolished histamine-induced DA cell
death. We suggest that oxidative stress induced by hista-
mine, such as the production of peroxynitrite formed by
the reaction between NO and O2−, may trigger PS exposure
on DA neurons which may become vulnerable to microglial
phagocytosis [14, 45]. This particular type of neuronal loss
referred as phagoptosis was also observed in animal models
of PD and could be prevented by using phagocytosis inhibi-
tors [69]. In fact, the "eat-me" signaling induced by PS ex-
posure was reversible, so that blocking of phagocytosis
through binding of PS by annexin V was sufficient to rescue
DA toxicity induced by histamine. Recent studies also
showed that microglial cells appear to migrate towards in-
toxicated/damaged DA neurons and present clear phago-
cytic characteristics, such as engulfing gliaptic contacts,
nucleation/clustering of the actin cytoskeleton, and an in-
crease in Golgi apparatus protein machinery in the SN of
both 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
treated mice and macaques [70, 71]. Gliaptic contacts in-
clude the contact of microglial cell processes and cell bod-
ies with DA neurites and cell bodies. Importantly, the
inhibition of Rho-associated kinase (ROCK) activity pre-
vents microglial migration and the formation of gliapses
to protect damaged DA neurons from elimination.
Altogether, both phagoptosis and the formation of gliaptic
contacts may be involved in the unnecessary phagocytic
elimination of DA neurons. Thus, blocking microglial mi-
gration and phagocytic activity might preserve degenerat-
ing neurons and induce neuroprotection. However, we
cannot exclude that higher histamine concentrations may
induce direct DA neuronal death without involving “pri-
mary phagocytosis” by microglia. In fact, we have previ-
ously shown that the secretome of histamine-treated
microglia cells trigger DA cell death in vitro [8], and the
direct application of histamine to a N27 rat DA cell line
was able to induce a slight reduction of cell viability (about
25 % reduction, data not show). This may suggest that his-
tamine induces DA cell loss by both soluble and contact
factors, and the contribution of each component may de-
pend on the complexity of the experimental model used
(in vivo versus in vitro) and the interaction with other brain
cells. Therefore, molecules that prevent neuroinflammation
and microglia activation, in particular microglial phagocyt-
osis, may offer prospective clinical therapeutic benefit for
neurodegenerative disease associated with an inflammatory
profile, such as PD. Yet, future studies are needed to fur-
ther disclose the role of histamine and antihistamines in
PD, by using toxin-induced (e.g., MPTP or 6-OHDA)
models combined with H1R conditional KO models to dis-
criminate the temporal and differential contribution of
H1R in both dopaminergic neurons and microglia. In ac-
cordance with our data, others also showed a neuroprotec-
tive and/or anti-inflammatory effect of antihistamines (e.g.,
H1R or H3R antagonists) in vivo in models of amyotrophic
lateral sclerosis [72], temporal lobe epilepsy [73], and ische-
mia [74]. In this context, histamine receptors, especially
microglia H1R, may be an interesting target to induce
neuroprotection in neuroinflammatory-related diseases.
Conclusions
In the healthy brain, histamine is present at nanomolar con-
centrations in the CSF of humans and rodents [75]. Import-
antly, circulating levels of histamine and histaminergic
innervations are robustly increased following brain injury
or degeneration. Under these pathological conditions, the
inflammatory response may trigger degranulation of mast
cells, leading to a massive release of histamine in the CSF
and in the brain parenchyma [22, 23, 76]. These evidences
support the pathophysiological relevance of the histamine
concentrations used in this study. Therefore, unraveling the
cellular and molecular mechanisms triggered by histamine
in neurodegenerative conditions, and particularly in PD, is
of outmost relevance. In particular, the role of histamine on
microglial activity has been recently uncovered and we were
the first to show that N9 microglial cells express all hista-
mine receptors and that histamine modulates microglial
motility and cytokine release [7]. Herein, we show that his-
tamine is an important modulator of microglial phagocyt-
osis and ROS production, both components involved in the
vulnerability and cell death of DA neurons in the SN in
vivo. To the best of our knowledge, we were the first to
show that the Nox signaling is involved in histamine-
induced neuroinflammation and neurodegeneration. Im-
portantly, histamine H1 antihistamines may be used as effi-
cient therapeutic targets to prevent histamine-induced
microglia activation and subsequent DA neuronal death in
the context of PD and, eventually, other neurodegenerative
diseases which are accompanied by microglia inflammation.
Additional files
Additional file 1: Figure S1. Histamine-induced ROS production via H1R
and H4R activation in primary microglial cell cultures. Cellular ROS production
induced by 100 μM histamine (H100) was blocked by an H1R antagonist
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(AntH1R, mepyramine maleate, 1 μM) or H4R antagonist (AntH4R,
JNJ7777120, 5 μM). Data are expressed as mean ± SEM (n = 5) and as
percentage of control. **P < 0.01 and ***P < 0.001, using one-way ANOVA
followed by Dunnett’s test. (TIF 251 KB)
Additional file 2: Figure S2. Nox2 and Nox4 expression. Bar graphs
depict Nox2 (A) and Nox4 (B) protein expression levels upon treatment
of microglial cells with 100 μM histamine for several time points. LPS
(100 ng/ml) was used as a positive control. Data are expressed as
mean ± SEM (n = 2–8) and as a percentage of control. *P < 0.05, one-way
ANOVA, Bonferroni’s multiple comparison test. (TIF 161 KB)
Additional file 3: Figure S3. Histamine-induced Nox1 immunostaining
in dopaminergic neurons in the SN in vivo. Representative confocal
photomicrographs showing that histamine-induced Nox1 expression in the
dopaminergic cells in the SN in vivo. Cells were stained for TH (green), Nox1
(red), and Hoechst 33342 (nuclei in blue). Scale bar 10 μm. (TIF 98 KB)
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